Author Archives for W2_Adm

Inventiva Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq Listing

July 6, 2020 6:44 pm Published by Comments Off on Inventiva Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq Listing

Daix (France), July 6, 2020 – Inventiva (Euronext Paris: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (“NASH”), mucopolysaccharidoses (“MPS”) and other diseases with significant unmet medical need, today announced the start of its roadshow in connection with its intention to issue and sell,...


H1 2020 Financial Information

July 6, 2020 6:25 pm Published by Comments Off on H1 2020 Financial Information

Daix (France), July 6, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today reported its cash position as of June 30, 2020. As of June 30, 2020, Inventiva’s cash and cash equivalents stood at €52.2 million compared...


Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2 diabetes patients (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)

July 6, 2020 8:10 am Published by Comments Off on Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2 diabetes patients (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)

Daix (France), July 6, 2020 – Inventiva (Euronext: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the decision by the investigator to reduce the number of patients to be enrolled in the investigator-initiated Phase II...


Inventiva provides a corporate business update in the context of the COVID-19 pandemic

April 7, 2020 6:08 pm Published by Comments Off on Inventiva provides a corporate business update in the context of the COVID-19 pandemic

Daix (France), April 7, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today provided an update on its business activities and financial position as well as the initiatives announced to support its employees and the local community amid the...


Inventiva files a prospectus in the context of the admission to trading of new shares on Euronext Paris

February 10, 2020 10:43 am Published by Comments Off on Inventiva files a prospectus in the context of the admission to trading of new shares on Euronext Paris

Daix (France), February 10, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that the French market authority (Autorité des Marchés Financiers, or AMF) approved a prospectus under number 20-034 on February 7, 2020 in the context of...